STOCK TITAN
  1. Home
  2. Sec-filings
  3. NAUT
  4. [Form 4] Nautilus Biotechnolgy, Inc. Insider Trading Activity

[Form 4] Nautilus Biotechnolgy, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

The filing is a Form 4 dated 06/24/2025 reporting insider activity at Nautilus Biotechnology, Inc. (ticker NAUT). Director Matthew L. Posard was granted a stock option covering 45,000 common shares at an exercise price of $0.6951 per share. The option was issued on 06/23/2025, vests in twelve equal monthly installments as long as Mr. Posard remains a “Service Provider,” and expires on 06/23/2035. After the transaction, Mr. Posard beneficially owns 45,000 derivative securities, all held directly. No common shares were bought or sold on the open market; the filing reflects an incentive-based equity award only.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Routine option grant; minimal near-term share impact, aligns director incentives.

The 45,000-share option grant to Director Posard is a standard equity incentive with a low exercise price relative to typical biotech valuations. Because it vests monthly over one year and no shares were sold, the filing signals neither insider buying nor selling pressure. The absolute size of the award is modest and unlikely to materially dilute shareholders. Overall, the event is neutral from a valuation or liquidity standpoint but does reinforce alignment between the board member and shareholders.

TL;DR: Governance-aligned incentive structure; no red flags detected.

The grant follows common governance practice for director compensation—short vesting horizon tied to continued service, reported promptly under Section 16. Absence of a 10b5-1 plan checkbox indicates the award was not part of a pre-arranged trading program, but because there is no sale, the governance risk is low. The filing demonstrates compliance and transparency with SEC requirements; no material concerns for investors.

Insider Posard Matthew L.
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 45,000 $0.00 $0.00
Holdings After Transaction: Stock Option (Right to Buy) — 45,000 shares (Direct)
Footnotes (1)
  1. F1. Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month).

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Posard Matthew L.
(Last) (First) (Middle)
C/O NAUTILUS BIOTECHNOLOGY, INC.
2701 EASTLAKE AVENUE EAST
(Street)
SEATTLE WA 98102
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Nautilus Biotechnology, Inc. [ NAUT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/23/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $0.6951 06/23/2025 A 45,000 (1) 06/23/2035 Common Stock 45,000 $0 45,000 D
Explanation of Responses:
1. Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each applicable vesting date, one-twelfth (1/12th) of the shares subject to the Option shall vest on a monthly basis following the date of grant on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month).
Remarks:
/s/ Mathew B. Murphy, as Attorney-in-Fact 06/24/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR